|
1
|
Jong TT, Lee MR, Hsiao SS, Hsai JL, Wu TS,
Chiang ST and Cai SQ: Analysis of aristolochic acid in nine sources
of Xixin, a traditional Chinese medicine, by liquid
chromatography/atmospheric pressure chemical ionization/tandem mass
spectrometry. J Pharm Biomed Anal. 33:831–837. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang HT, Wang YM, Liang YP, Liu YJ and
Peng W: Wenyang Huoxue Recipe up-regulates the expression of
angiopoietin-1 mRNA in rats with chronic aristolochic acid
nephropathy. Zhong Xi Yi Jie He Xue Bao. 6:508–511. 2008.(In
Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grollman AP: Aristolochic acid
nephropathy: Harbinger of a global iatrogenic disease. Environ Mol
Mutagen. 54:1–7. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nortier JL, Schmeiser HH, Martinez MC
Muniz, Arlt VM, Vervaet C, Garbar CH, Daelemans P and Vanherweghem
JL: Invasive urothelial carcinoma after exposure to Chinese herbal
medicine containing aristolochic acid may occur without severe
renal failure. Nephrol Dial Transplant. 18:426–428. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vanherweghem JL, Depierreux M, Tielemans
C, Abramdwicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D,
Verbeelen D, Vanhaelen-Fastre R, et al: Rapidly progressive
interstitial renal fibrosis in young women: Association with
slimming regimen including Chinese herds. Lancet. 341:387–391.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaudry H, Leprince J, Chatenet D, Fournier
A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H
and Vaudry D: International union of basic and clinical
pharmacology. XCII. Urotensin II, urotensin II-related peptide, and
their receptor: From structure to function. Pharmacol Rev.
67:214–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Egginger JG, Camus A and Calas A:
Urotensin-II expression in the mouse spinal cord. J Chem Neuroanat.
31:146–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jegou S, Cartier D, Dubessy C, Gonzalez
BJ, Chatenet D, Tostivint H, Scalbert E, LePrince J, Vaudry H and
Lihrmann I: Localization of the urotensin II receptor in the rat
central nervous system. J Comp Neurol. 495:21–36. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diebold I, Petry A, Burger M, Hess J and
Görlach A: NOX4 mediates activation of FoxO3a and matrix
metalloproteinase-2 expression by urotensin-II. Mol Biol Cell.
22:4424–4434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu W, Abdel-Razik AE, Ashton N and Balment
RJ: Urotensin II: Lessons from comparative studies for general
endocrinology. Gen Comp Endocrinol. 157:14–20. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Richards AM and Charles C: Urotensin II in
the cardiovascular system. Peptides. 25:1795–1802. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen SX, Li C, Miao CS, Zhang XY and Fan
Z: Mitogenic effect of urotensin II on the renal tubular epithelial
cells in rats. J Jilin Univ (Med Ed). 33:204–206. 2007.(In
Chinese).
|
|
13
|
Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY,
Chen YC, Lin SL, Chen TW and Chen TH: Urotensin II induces
transactivation of the epidermal growth factor receptor via
transient oxidation of SHP-2 in the rat renal tubular cell line
NRK-52E. Growth Factors. 27:155–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abdel-Razik AE, Forty EJ, Balment RJ and
Ashton N: Renal haemodynamic and tubular actions of urotensin II in
the rat. J Endocrinol. 198:617–624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adebiyi A: RGS2 regulates urotensin
II-induced intracellular Ca2+ elevation and contraction in
glomerular mesangial cells. J Cell Physiol. 229:502–511. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu YH, Chen TH, Chen YC, Cheng CY, Sue
YM, Chen JR and Chen CH: Urotensin II exerts antiapoptotic effect
on NRK-52E cells through prostacyclin-mediated peroxisome
proliferator-activated receptor alpha and Akt activation. Mol Cell
Endocrinol. 381:168–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yilmaz B, Yilmaz A, Sari F, Sarikaya AM,
Ellidag HY, Kucukseymen S and Ozpelit E: Decrease of Urotensin II
activity can impact on the volume status in predialysis chronic
kidney disease. Ren Fail. 37:476–481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian L, Li C, Qi J, Fu P, Yu X, Li X and
Cai L: Diabetes-induced upregulation of urotensin II and its
receptor plays an important role in TGF-beta1-mediated renal
fibrosis and dysfunction. Am J Physiol Endocrinol Metab.
295:E1234–E1242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S and Wan Y: The effect of
Aristolochic acid on UII and GPR14 mRNA levels in the renal tubular
epithelial cells. Shandong Pharm. 52:36–38. 2012.(In Chinese).
|
|
20
|
Ruiz-Torres MP, Bosch RJ, O'Valle F, Del
Moral RG, Ramírez C, Masseroli M, Pérez-Caballero C, Iglesias MC,
Rodríguez-Puyol M and Rodríguez-Puyol D: Age-related increase in
expression of TGF-beta1 in the rat kidney: Relationship to
morphologic changes. J Am Soc Nephrol. 9:782–791. 1998.PubMed/NCBI
|
|
21
|
Lúdvíksson BR, Seegers D, Resnick AS and
Strober W: The effect of TGF-beta1 on immune responses of naive
versus memory CD4+ Th1/Th2 T cells. Eur J Immunol. 30:2101–2111.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng H, Zhou Y and Yao GY: Transforming
growth factor beta 1 induces the transdifferentiation of human
renal tubular epithelial cells: the influence of Notch1 receptor
specific inhibitor. Chin J Clin Rehabilitative Tissue Engineering
Res. 18:8261–8268. 2014.(In Chinese).
|
|
23
|
Docherty NG, Pérez-Barriocanal F, Balboa
NE and López-Novoa JM: Transforming growth factor-beta1
(TGF-beta1): A potential recovery signal in the post-ischemic
kidney. Ren Fail. 24:391–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hwang M, Kim HJ, Noh HJ, Chang YC, Chae
YM, Kim KH, Jeon JP, Lee TS, Oh HK, Lee YS and Park KK: TGF-beta1
siRNA suppresses the tubulointerstitial fibrosis in the kidney of
ureteral obstruction. Exp Mol Pathol. 81:48–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang XR, Chung AC, Wang XJ, Lai KN and
Lan HY: Mice overexpressing latent TGF-beta1 are protected against
renal fibrosis in obstructive kidney disease. Am J Physiol Renal
Physiol. 295:F118–F127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basile DP, Martin DR and Hammerman MR:
Extracellular matrix-related genes in kidney after ischemic injury:
Potential role for TGF-beta in repair. Am J Physiol. 275:F894–F903.
1998.PubMed/NCBI
|
|
27
|
Spurgeon KR, Donohoe DL and Basile DP:
Transforming growth factor-beta in acute renal failure: Receptor
expression, effects on proliferation, cellularity, and
vascularization after recovery from injury. Am J Physiol Renal
Physiol. 288:F568–F577. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gobe G, Zhang XJ, Willgoss DA, Schoch E,
Hogg NA and Endre ZH: Relationship between expression of Bcl-2
genes and growth factors in ischemic acute renal failure in the
rat. J Am Soc Nephrol. 11:454–467. 2000.PubMed/NCBI
|
|
29
|
Kemp W, Kompa A, Phrommintikul A, Herath
C, Zhiyuan J, Angus P, McLean C, Roberts S and Krum H: Urotensin II
modulates hepatic fibrosis and portal hemodynamic alterations in
rats. Am J Physiol Gastrointest Liver Physiol. 297:G762–G767. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang YG, Hu YC, Mao YY, Wei RH, Bao SL,
Wu LB and Kuang ZJ: Transforming growth factor-β1 involved in
urotensin II-induced phenotypic differentiation of adventitial
fibroblasts from rat aorta. Chin Med J (Engl). 123:3634–3639.
2010.PubMed/NCBI
|
|
31
|
Weiskirchen R and Meurer SK: BMP-7
counteracting TGF-beta1 activities in organ fibrosis. Front Biosci
(Landmark Ed). 18:1407–1434. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samarakoon R, Overstreet JM, Higgins SP
and Higgins PJ: TGF-β1→SMAD/p53/USF2→PAI-1 transcriptional axis in
ureteral obstruction-induced renal fibrosis. Cell Tissue Res.
347:117–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai HY, He T, Li XL, Xu WL and Ge ZM:
Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and
ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts. Cell
Biol Int. 35:93–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Onat AM, Turkbeyler IH, Pehlivan Y, Demir
T, Kaplan DS, Taysi S, Ceribasi AO, Tutar E and Kisacik B: The
efficiency of a urotensin II antagonist in an experimental lung
fibrosis model. Inflammation. 35:1138–1143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tzanidis A, Hannan RD, Thomas WG, Onan D,
Autelitano DJ, See F, Kelly DJ, Gilbert RE and Krum H: Direct
actions of urotensin II on the heart: Implications for cardiac
fibrosis and hypertrophy. Circ Res. 93:246–253. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang YG, Li YG, Liu BG, Wei RH, Wang DM,
Tan XR, Bu DF, Pang YZ and Tang CS: Urotensin II accelerates
cardiac fibrosis and hypertrophy of rats induced by isoproterenol.
Acta Pharmacol Sin. 28:36–43. 2007. View Article : Google Scholar : PubMed/NCBI
|
